World journal of surgical oncology · 2025
Mapping the landscape of ovarian metastases of gastric cancer: insights, trends, and emerging perspectives.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Liping, Fu Tong, Chen Yuqing, Zhang Xu
Аннотация
BACKGROUND: Gastric cancer (GC) has poor prognosis due to distant metastasis with ovarian metastasis (OM) occurring in 5-10% of female patients and survival limited to 7-14 months. No standard treatment exists. This review analyzes global research and trends in OM management.
METHODS: Publications on OM in GC (1991-2024) were retrieved from the Web of Science Core Collection. Bibliometric analysis of 324 articles was performed using CiteSpace and VOSviewer.
RESULTS: Three main themes emerged: (1) diagnosis and pathology characteristics of OM, (2) treatment and management, and (3) clinical features in special populations, such as pregnancy.
CONCLUSION: Research hotspots include multidisciplinary treatment (MDT), diagnostic tumor markers (e.g., CA125, CA19-9, and carcinoembryonic antigen (CEA)), imaging (e.g., MRI, ultrasound), and novel approaches such as immunotherapy and targeted therapy (Microsatellite Instability-High (MSI - H), Tumor Mutational Burden-High (TMB - H). Future directions call for multicenter clinical trials and interdisciplinary collaboration to improve patient outcomes.
METHODS: Publications on OM in GC (1991-2024) were retrieved from the Web of Science Core Collection. Bibliometric analysis of 324 articles was performed using CiteSpace and VOSviewer.
RESULTS: Three main themes emerged: (1) diagnosis and pathology characteristics of OM, (2) treatment and management, and (3) clinical features in special populations, such as pregnancy.
CONCLUSION: Research hotspots include multidisciplinary treatment (MDT), diagnostic tumor markers (e.g., CA125, CA19-9, and carcinoembryonic antigen (CEA)), imaging (e.g., MRI, ultrasound), and novel approaches such as immunotherapy and targeted therapy (Microsatellite Instability-High (MSI - H), Tumor Mutational Burden-High (TMB - H). Future directions call for multicenter clinical trials and interdisciplinary collaboration to improve patient outcomes.